Download Files:
Ponatinib
$42 – $158
Products Details
Product Description
– Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].
Web ID
– HY-12047
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H27F3N6O
Citations
– Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Biochem Pharmacol. 2021 Jul 30;114710.|Biomolecules. 2022 Jun 11;12(6):819.|Cancer Discov. 2021 Jan;11(1):126-141.|Clin Chim Acta. 2018 May;480:180-185. |Eur J Pharmacol. 2020 Dec 15;889:173292.|Exp Hematol. 2014 May;42(5):369-379.e3.|Fundam Clin Pharmacol. 2021 Feb 1.|Harvard Medical School LINCS LIBRARY|J Ethnopharmacol. 2023 Feb 17;116275.|J Med Chem. 2019 May 23;62(10):5006-5024. |Leuk Res. 2016 Jun;45:24-32. |Neurosci Bull. 2020 Mar;36(3):263-276.|Pharmaceuticals. 2022, 15(9), 1073.|Pharmacogn Mag. 2023 Jul 20.|PLoS One. 2021 Sep 30;16(9):e0258140.|PLoS One. 2022 Feb 14;17(2):e0263822.|Research Square Preprint. 2021 May.|Research Square Print. 2023 Mar 23.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Target Oncol. 2020 Oct;15(5):659-671.|Technical University of Munich. 24.01.2018.|Biomaterials. 16 September 2022.
References
– [1]O’Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.|[2]Gozgit JM, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther, 2011, 10(6), 1028-1035.|[3]Uchida T, et al. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Exp Hematol. 2014 May;42(5):369-379.e3.
CAS Number
– 943319-70-8
Molecular Weight
– 532.56
Compound Purity
– 99.43
SMILES
– CC1=C(C=C(C=C1)C(NC2=CC(C(F)(F)F)=C(C=C2)CN3CCN(CC3)C)=O)C#CC4=CN=C5N4N=CC=C5
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– 1M HCl : 50 mg/mL (ultrasonic;adjust pH to 1 with HCl)|DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Autophagy;Bcr-Abl;FGFR;PDGFR;Src;VEGFR
Isoform
– FGFR1;PDGFRα;VEGFR2/KDR/Flk-1
Pathway
– Autophagy;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
